To examine differences in sleep disturbance, nocturia, and depression among adults with overactive bladder (OAB) by treatment type.
A cross-sectional survey of adults with OAB assessed sleep disturbance, nocturia, and depression using patient-reported outcome measures, including the Patient Reported Outcomes Measurement Information System (PROMIS®)-29 Profile v2. 1 (Sleep Disturbance and Depression domains), Lower Urinary Tract Dysfunction Research Network Symptom Index-10, and PROMIS® Sleep Disturbance Short Form 8B. Treatment groups included antimuscarinics, β-3 adrenergic agonists, and no treatment. Analysis of covariance (ANCOVA) was used to test for differences in study endpoints; Bonferroni-adjusted pairwise tests (p<0.05/3) were performed to compare differences in least squares means between groups.
One hundred participants were included per treatment group. The overall mean (standard deviation) age across all groups was 47.8 (11.8) years. Symptom scores across all PROMIS domains in all three treatment groups were higher than the US general population. There were no statistically significant differences in outcomes across treatment groups.
Adults with OAB reported being affected by sleep disturbance and depression, regardless of treatment. The mirabegron group trended toward the lowest symptom impact across all outcomes, however comparisons were not significant. Future research should examine temporal associations between OAB treatment, sleep disturbance, and outcomes.
Urology. 2023 Jun 23 [Epub ahead of print]
H H Lai, D Walker, D Elsouda, A Lockefeer, K Gallington, E D Bacci
Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St Louis, MO, USA., Astellas Global Pharma Development, Inc., Northbrook, IL, USA. Electronic address: ., Astellas Global Pharma Development, Inc., Northbrook, IL, USA., Evidera, Seattle, WA, USA.